CEO Update: January 2020
Insitu Biologics continues to make rapid progress towards our mission of providing patients and physicians with an opioid-free solution for post-operative pain. We have added exceptional talent to our team, are nearing manufacturability of clinical-grade product, are in communication with the FDA regarding our clinical strategy moving forward, and have engaged in fundraising on several fronts. Thank you to everyone who has invested in this disruptive technology to curb the opioid crisis and provide a better safer solution for patients in post-operative pain.
For any final investments in our company via the open Reg A+ (click here to invest). Please take some time to read our company update by clicking the preview image below: